Monocyte chemotactic protein-1 (MCP1) and the PTH anabolic effect in bone.

单核细胞趋化蛋白-1 (MCP1) 和骨中 PTH 合成代谢作用。

• 批准号: nhmrc : 597481
• 负责人: A/Pr Nigel Morrison
• 金额: $ 46.04万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/monocyte-chemotactic-protein-effect-bone/99287
• 关键词: Monocyte; chemotactic; protein; MCP1; PTH

Chemokines and their receptors are major regulators of cell-cell interactions in many tissues. This project explores the strong increase of monocyte chemotactic protein-1 (MCP1 or CCL2) in bone, in a treatment where parathyroid hormone (a controller of calcium homeostasis) is used to increase bone mass to prevent osteoporosis. MCP1 was previously thought to be an inflammatory regulator, induced during infection and important in autoimmune conditions, so its role in bone was highly unexpected.

趋化因子及其受体是许多组织中细胞间相互作用的主要调节因子。该项目探讨了骨中单核细胞趋化蛋白-1（MCP 1或CCL 2）的强烈增加，在甲状旁腺激素（钙稳态的控制器）用于增加骨量以预防骨质疏松症的治疗中。MCP 1以前被认为是一种炎症调节因子，在感染期间诱导，在自身免疫性疾病中很重要，因此它在骨中的作用非常出乎意料。